PH
PH
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
24 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
PH has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%. PH ranks #202 in insider activity out of 247 tracked companies in its industry.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at PH (PH) engaged in a total of 24 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for PH shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 4.4K shares valued at $0 on Sep 8, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering PH and the Unknown sector.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
Deciphering Form 5 Filings: Uncovering Annual Insider Gift Trades
A comprehensive guide to SEC Form 5 filings, explaining how annual reports of gift shares, stock options, and non-open-market transactions signal insider sentiment.
The Quant Guide: Backtesting SEC Form 4 Cluster Buys for Alpha
A rigorous quantitative backtest of SEC Form 4 cluster buying activity, demonstrating how to isolate signal from noise and build portfolios that consistently outperform benchmarks.
The Y Combinator Spinoff Trade: Spotting Alpha in Post-Demo Day IPOs
Y Combinator alumni companies show distinctive insider liquidity patterns after IPO. This report maps Form 4 activity at YC-backed public companies to identify when founder and early-investor selling subsides and conviction buying begins.
The Role of Insider Trading in M&A: Deciphering the Pre-Merger Signals
M&A deals are the most fertile ground for illegal insider trading, and for legal cluster buys that signal a company is strategically attractive. This guide separates the legal signal from the illegal noise in M&A-adjacent Form 4 activity.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
FAQs About PH Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for PH.